[Prevalence and geographical distribution of bovine sexually transmitted diseases in the province of Formosa, Argentina]. / Prevalencia y distribución geográfica de las enfermedades de transmisión sexual de los bovinos en la provincia de Formosa, Argentina.

Bovine genital campylobacteriosis (BGC) and bovine trichomonosis (BT) are sexually transmitted diseases (STDs) that affect bovine breeding herds, decreasing their reproductive efficiency. The objective of this work was to estimate the prevalence of these diseases and their temporal-spatial distribution in the province of Formosa, Argentina. The cross-sectional study conducted between 2018 and 2021 included a total of 15,571 bulls, inter-herd prevalence being 29.62% and 17.23% for BGC and BT, respectively. The prevalence of positive animals was 2.05% for BGC and 0.43% for BT. The temporal-spatial analysis of BGC showed two distinct spatial groupings, one group had a low risk of contracting the disease (RR = 0.13; p < 0.001; 2018-2021) while the other group had a high risk (RR = 2.84; p < 0.001; 2020-2021). BT had a high-risk group for the disease (RR = 35.24; p < 0.001; 2019). This study shows that STDs are endemic in the region, providing updated and valuable information as a tool for the health management of these diseases.

Real-life evidence about the use of intravenous brivaracetam in urgent seizures: The BRIV-IV study.

PURPOSE: Urgent seizures are a medical emergency for which new therapies are still needed. This study evaluated the use of intravenous brivaracetam (IV-BRV) in an emergency setting in clinical practice. METHODS: BRIV-IV was a retrospective, multicenter, observational study. It included patients ≥18 years old who were diagnosed with urgent seizures (including status epilepticus (SE), acute repetitive seizures, and high-risk seizures) and who were treated with IV-BRV according to clinical practice in 14 hospital centers. Information was extracted from clinical charts and included in an electronic database. Primary effectiveness endpoints included the rate of IV-BRV responder patients, the rate of patients with a sustained response without seizure relapse in 12 h, and the time between IV-BRV administration and clinical response. Primary safety endpoints were comprised the percentage of patients with adverse events and those with adverse events leading to discontinuation. RESULTS: A total of 156 patients were included in this study. The mean age was 57.7 ± 21.5 years old with a prior diagnosis of epilepsy for 57.1% of patients. The most frequent etiologies were brain tumor-related (18.1%) and vascular (11.2%) epilepsy. SE was diagnosed in 55.3% of patients. The median time from urgent seizure onset to IV treatment administration was 60.0 min (range: 15.0-360.0), and the median time from IV treatment to IV-BRV was 90.0 min (range: 30.0-2400.0). Regarding dosage, the mean bolus infusion was 163.0 ± 73.0 mg and the mean daily dosage was 195.0 ± 87.0 mg. A total of 77.6% of patients responded to IV-BRV (66.3% with SE vs. 91% other urgent seizures) with a median response time of 30.0 min (range: 10.0-60.0). A sustained response was achieved in 62.8% of patients. However, adverse events were reported in 14.7%, which were predominantly somnolence and fatigue, with 4.5% leading to discontinuation. Eighty-six percent of patients were discharged with oral brivaracetam. CONCLUSION: IV-BRV in emergency settings was effective, and tolerability was good for most patients. However, a larger series is needed to confirm the outcomes.

Performance in the treatment of municipal waste: Are European Union member states so different?

Efficient management and treatment of municipal waste is essential for achieving green growth. Recent studies have revealed convergence in European Union (EU) member states' performance in municipal waste treatment, particularly since the transposition of the 2008 European Waste Framework Directive into national laws. However, there are still notable differences between countries. In this paper, we calculate a composite indicator of performance in municipal waste treatment at the country-level. We also present an in-depth examination of differences in performance across EU member states. Our results show that the best performers-mainly high income Northern and Central European countries-treat larger quantities of waste per capita, mostly through recycling and composting and digestion. At the opposite end of the ranking, the worst performers-mostly poorer Eastern European countries-treat smaller amounts of waste per capita, largely through landfilling. Our main conclusion is that further policy measures aimed at reducing cross-country differences in waste treatment performance are needed in the EU.

Performance and convergence in municipal waste treatment in the European Union.

This paper assesses performance and convergence in the treatment of municipal waste by the members of the European Union-27 (EU-27) during the period 1995-2016. First, a composite indicator of performance -including landfill, incineration, recycling, and composting and digestion as treatment operations- is computed with Data Envelopment Analysis and Multi-Criteria-Decision-Making techniques at country and year levels. Then, convergence is assessed using the techniques proposed by Phillips and Sul (2007, 2009) and, more recently, by Kong et al. (2017). The best performers are Central and Northern European countries such as Denmark, Austria and Germany, whereas the worst are some Eastern European countries that joined the European Union in the 2000s. Furthermore, performance has largely converged among EU-27 countries since the enactment of the current Waste Framework Directive in 2008.